Genomics papers can have author lists that seem to stretch down the block, but much of the credit is often awarded to the first and senior authors. Those in the middle of the list — researchers who might've contributed key bioinformatics analyses to the project — can be overlooked, the Chronicle of Higher Education says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.